Vinay Prasad1, Jeffery A Goldstein2. 1. Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr. 10/12N226, Bethesda, MD 20892, United States. Electronic address: vinayakkprasad@gmail.com. 2. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States. Electronic address: jeffery.a.goldstein@vanderbilt.edu.
Abstract
BACKGROUND: Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. METHODOLOGY: We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. RESULTS: From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrollment varied by tumour type, with both over and under-representation occurring. CONCLUSION: Opportunities to enroll in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials. Published by Elsevier Ltd.
BACKGROUND: Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. METHODOLOGY: We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. RESULTS: From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrollment varied by tumour type, with both over and under-representation occurring. CONCLUSION: Opportunities to enroll in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials. Published by Elsevier Ltd.
Entities:
Keywords:
Burden of disease; Cancer clinical trials; Cancer trials; Cancer trials portfolio; Clinicaltrials.gov; Phase I, phase II and phase III
Authors: Rachel F Dear; Alexandra L Barratt; Kevin McGeechan; Lisa Askie; John Simes; Martin H N Tattersall Journal: Med J Aust Date: 2011-04-18 Impact factor: 7.738
Authors: Robert M Califf; Deborah A Zarin; Judith M Kramer; Rachel E Sherman; Laura H Aberle; Asba Tasneem Journal: JAMA Date: 2012-05-02 Impact factor: 56.272
Authors: Joseph M Unger; Dawn L Hershman; Kathy S Albain; Carol M Moinpour; Judith A Petersen; Kenda Burg; John J Crowley Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245